Europe Holter ECG Market to Grow at a CAGR of 8.0% to reach US$ 322.07 million from 2021 to 2028

The Europe Holter ECG market is expected to grow from US$ 203.03 million in 2022 to US$ 322.07 million by 2028; it is estimated to grow at a CAGR of 8.0% from 2022 to 2028. 

The growth of the Europe Holter ECG market is attributed to the rising geriatric population. However, the lack of skilled professionals leading to inaccurate Holter ECG analysis is hindering the market growth.

CVDs continue to be the leading cause of mortality and a major cause of morbidity in Europe. According to the European Society of Cardiology 2023 report, more than six million new cases of CVD in the EU are registered annually. This is mainly due to smoking, alcohol consumption, and levels of mean blood cholesterol. Moreover, with the rising cases of CVDs in Europe, the healthcare costs are also increasing, accounting for US$ 228.46 billion annually. The European Society of Cardiology reported that patients suffering from atrial fibrillation are at a five-times greater risk of getting a stroke, and 20–30% of total stroke cases in Europe are caused due to atrial fibrillation. The growing prevalence of arrhythmia and other cardiovascular diseases (CVDs) is encouraging the introduction of improved diagnostic methods.

In the last decade, the world witnessed notable developments in Holter ECG monitors, aiding physicians and patients with new approaches to manage diseases such as atrial arrhythmias, ventricular arrhythmias, and ventricular atrial fibrillation. Holter ECG monitors are gaining significant traction as these are simpler and quicker tools used for detecting arrhythmias. Holter monitoring is noninvasive, safer, and effective for patient monitoring. Therefore, a 24-hour Holter monitor is widely adopted in Europe and intended for the early detection of arrhythmias in patients suffering from a high clinical suspicion of atrial fibrillation (AF). For example, a 24-hour Holter monitor in a clinical study has revealed a 96.3% sensitivity and 96.8% specificity for the detection of AF. Most types of CVDs can be prevented through pre-monitoring and pre-diagnosis. Likewise, arrhythmias, i.e., abnormalities in the heart functioning, can be averted with early diagnosis. The demand for arrhythmia monitoring devices is increasing as these devices can help save patients at a high risk of cardiac arrest. This results in the adoption of new and innovative devices by the healthcare industry that help provide enhanced medical care and better healthcare facilities, which, in turn, is boosting demand for monitoring devices such as Holter ECG monitors. To avoid risks associated with CVDs, Holter ECGs are widely used by people likely to be exposed to factors that cause CVD. A Holter ECG monitor records the heart's activity (ECG) continuously for 24–48 hours, which is essential for safe diagnosis and therapy control. This is a major factor fueling its demand. Thus, the rising incidence of CVDs in Europe is increasing the demand for Holter ECG.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Europe Holter ECG Market: Strategic Insights

Market Size Value in	US$ 203.03 million in 2022
Market Size Value by	US$ 322.07 million by 2028
Growth rate	CAGR of 8.0% from 2022 to 2028
Forecast Period	2022-2028
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

The UK held the largest market share for the Holter ECG market in 2021. According to the Stroke Association report, over 1 million people in the UK suffer from atrial fibrillation (AF), with half a million people having undiagnosed atrial fibrillation (AF). Also, it is estimated that there are approximately 270,000 people aged over 65 in the UK suffering from undiagnosed (or silent) AF. Similarly, in the report published in the Public Library of Science (PLoS) in the UK, the treatment of CVD costs ~US$ 14.16 billion, out of the budget of National Healthcare Services (NHS). As per the ClinicalTrials.gov report, a conventional 24-hour Holter monitoring device is used to detect paroxysmal atrial fibrillation. Also, a serial 12-lead ECG product is used for detecting possible paroxysmal atrial fibrillation in patients suffering from acute ischemic stroke.

Therefore, the demand for Holter ECG is growing with the rising prevalence of atrial fibrillation and CVDs across the country, which is expected to support the overall market growth during the forecast period.

Lucrative Countries for Holter ECG Market

Component-Based Insights

Based on component, the Europe Holter ECGs market is segmented into products, software & solutions, services, and accessories. The products segment held the largest share of the market in 2021. However, the software & solutions segment is expected to register the highest CAGR in the market during the forecast period. Holter monitoring software has advanced remarkably in recent years. Most companies have useful analytical software that can be used to generate halter monitoring reports quickly and accurately. 

In addition, many halter companies offer advanced reporting capabilities through intelligent ECG algorithms. Market players are launching new products for market development. For instance, in Nov 2020, Abbott launched the new EnSite X EP System and received CE Mark and approval throughout Europe and Australia. The EnSite X System offered the option to navigate the cardiac anatomy two different ways on one platform and expanded the company’s electrophysiology portfolio. Cardiac mapping systems allowed electrophysiologists to create a heart map and helped them get a clear picture of the electrical signals that control cardiac rhythms.

In Sept 2021, Johnson & Johnson (Biosense Webster) announced successful post-approval procedures with the first-ever HELIOSTAR Balloon Ablation Catheter, a radiofrequency balloon ablation catheter at sites across Europe. In Europe, the catheter was used in the cardiac electrophysiological mapping of the atria and for cardiac ablation.

Access Data

Application-Based Insights         

Based on application, the Europe Holter ECGs market is bifurcated into diagnostics and monitoring. The diagnostics segment held a larger share of the market in 2021. However, the monitoring segment is anticipated to register a higher CAGR in the market from 2022 to 2028. A Holter monitor provides a complete picture of heart activity necessary for the diagnosis of cardiac conditions. The monitor records the heart’s behavior continuously. An electrocardiogram is a painless, noninvasive way to help diagnose many common heart problems in people of all ages. However, it may not provide as comprehensive of results as is received from the Holter monitor. As the Holter ECG displays the electrical activity of the heart, which is useful for determining irregular heart rate and heart rhythm abnormalities. It can also be used to diagnose coronary heart disease or the occurrence of a heart attack. Finally, a routine ECG can help to monitor the effects of prescribed cardiac medication.

The device is simple to operate, and it does not require additional medical training from the user. They are increasing the patient's comfort by telemonitoring at home and mobility of the device, which allows patients to function normally in their daily routines. Furthermore, the increasing prevalence of conditions such as cardiovascular diseases is also likely to boost segment growth. In addition, age-related conditions such as heart disease are also expected to boost the growth of the home settings segment by 2028.

Companies operating in the Europe Holter ECG market adopt the product innovation strategy to meet the evolving customer demands worldwide, permitting them to maintain their brand name in the market.

Company Profiles

• FUKUDA DENSHI          
• General Electric Co  
• EB Neuro S.P.A   
• Koninklijke Philips NV        
• Viatom Technology Co., Ltd.      
• Nihon Kohden Corp
• INNOMED MEDICAL ZRT
• OSI Systems, Inc.
• Hill Rom Holding Inc. (Baxter)
• Custo med GmbH.